PainReform (PRFX) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

PRFX PainReform

Watchlist

3.5000
-1.4000-28.57%

Close Dec 27 16:00 ET

3.6500
+0.1500+4.29%

Post 18:51 ET

3.06MMarket Cap-0.02P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

PainReform Shares Are Trading Lower. The Company Announced an Update Regarding Its Phase 3 Clinical Trial Evaluating PRF-110 in Post-surgical Pain Management of Patients Undergoing Bunionectomy.
Benzinga12:43 ET
Express News | PainReform Shares Down 24.9% Premarket After Pain Relief Treatment Fails to Meet Main Goal in Late Stage Trial
ReutersDec 27 09:08 ET
PainReform Down 38% After Resuming Trading
TipRanksDec 27 09:05 ET
PainReform Phase 3 Trial on PRF-110 Did Not Meet Primary Endpoint
TipRanksDec 27 08:35 ET
Express News | PainReform Ltd: Data From Final 24-Hour Period Could Not Be Clarified to Satisfy Study's Primary Endpoint 72 Hours Requirement
ReutersDec 27 08:30 ET
PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110
GlobeNewswireDec 27 08:30 ET

Comments

Moupali Mukherjee

9 hours ago

$PainReform (PRFX.US)$ is it still a strong buy even thought he news are not showing postive result?

Trytosaveabit

10 hours ago

News!

$PainReform (PRFX.US)$ Reuters· 4 mins ago
PainReform Ltd: Data From Final 24-Hour Period Could Not Be Clarified to Satisfy Study's Primary Endpoint 72 Hours Requirement

DigTheDip

10 hours ago

$PainReform (PRFX.US)$ PainReform (Nasdaq: PRFX) provided an update on its Phase 3 clinical trial of PRF-110 for post-surgical pain management in bunionectomy patients. While the trial showed statistically significant superiority over placebo in pain reduction during the first 48 hours post-surgery, the company revealed that data from the final 24-hour period could not be clarified to meet the study's primary endpoint 72-hour requirement. As a result, the trial did not achieve its primary endpoin...